Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Literature DB >> 8302342

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

J T Beck¹, S M Hsu, J Wijdenes, R Bataille, B Klein, D Vesole, K Hayden, S Jagannath, B Barlogie.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 1994 PMID： 8302342 DOI： 10.1056/NEJM199403033300904

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

70 in total

1. Interleukin-6-producing dermoid cyst associated with multicentric Castleman's disease.

Authors: Shigeyuki Ebara; Soken-Nakazawa J Song; Hiroyuki Mizuta; Yasushi Ito; Kenji Hasegawa; Tsuneko Kamata; Teppei Matsumura-Nishikawa; Takafumi Ogawa; Jyunichi Soneda; Kazuyuki Yoshizaki
Journal: Int J Hematol Date: 2011-12-14 Impact factor: 2.490

Review 2. Video assisted thoracoscopic resection of a posterior mediastinal Castleman's tumor.

Authors: Shohan Shetty; Robert A Brenes; Lucian Panait; Juan A Sanchez
Journal: J Cardiothorac Surg Date: 2011-09-20 Impact factor: 1.637

3. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

Authors: J-F Rossi; N Fegueux; Z Y Lu; E Legouffe; C Exbrayat; M-C Bozonnat; R Navarro; E Lopez; P Quittet; J-P Daures; V Rouillé; T Kanouni; J Widjenes; B Klein
Journal: Bone Marrow Transplant Date: 2005-11 Impact factor: 5.483

4. Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

Authors: D Zagury; A Burny; R C Gallo
Journal: Proc Natl Acad Sci U S A Date: 2001-07-03 Impact factor: 11.205

5. IL-6 and TNF-alpha synergistically inhibit allograft acceptance.

Authors: Hua Shen; Daniel R Goldstein
Journal: J Am Soc Nephrol Date: 2009-04-08 Impact factor: 10.121

6. Assessment of pathologically diagnosed patients with Castleman's disease associated with diffuse parenchymal lung involvement using the diagnostic criteria for IgG4-related disease.

Authors: Takaaki Ogoshi; Takashi Kido; Kazuhiro Yatera; Keishi Oda; Toshinori Kawanami; Hiroshi Ishimoto; Noriho Sakamoto; Arisa Sano; Chiharu Yoshii; Shohei Shimajiri; Hiroshi Mukae
Journal: Lung Date: 2013-08-13 Impact factor: 2.584

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

1. Interleukin-6-producing dermoid cyst associated with multicentric Castleman's disease.

Review 2. Video assisted thoracoscopic resection of a posterior mediastinal Castleman's tumor.

3. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

4. Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

5. IL-6 and TNF-alpha synergistically inhibit allograft acceptance.

6. Assessment of pathologically diagnosed patients with Castleman's disease associated with diffuse parenchymal lung involvement using the diagnostic criteria for IgG4-related disease.

7. Anemia resolved by thoracoscopic resection of a mediastinal mass: a case report of unicentric Castleman's disease.

Review 8. Biologic Agents in the Treatment of Multicentric Castleman Disease.

9. Cervical Castleman's disease associated with benign M-proteinemia: report of a case.

10. Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation.